Myocardial infarction Heart attack
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Outpatients being treated for stable cardiovascular disease by the cardiology department. - Stable cardiovascular disease defined as: coronary artery disease, peripheral vascular disease or previous myocardial infarction. - Intake of 80 mg of acetylsalicylic acid once a day
Exclusion criteria
Exclusion criteria: - Active bleeding - Diabetes mellitus - Thrombocytopenia - Thrombocytosis - Valvualar heart disease/dysfunction - Thrombopathy (e.g. von Willebrand disease, Glanzmann*s thrombasthenia and Bernard-Soulier syndrome) ; - Any ischemic event or revascularization procedure (percutaneous coronary intervention or coronary artery bypass grafting) within the last six months; - Alcohol intake the day before blood sampling; - Non-compliance to the protocol ; - Baxter rolls (i.e. presorted medicine by a pharmacist) ; - Recent use of antiplatelet drugs, anticoagulants or drugs that are known to alter platelet function, other than aspirin (e.g. NSAID*s, tirofiban, eptifibatide, abciximab, beta-lactam antibiotics, dextran, SSRI*s, clomipramine & amitriptyline, dipyridamole, verapamil, diltiazem , ginkgo biloba, ginseng, St John*s wort). ;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will analyze whether a twice daily regimen is superior to a once daily regime of aspirin when it comes to inhibiting platelet aggregation in cardiovascular patients, as measured by the PFA-200, Chrono-log light transmission aggregometry, VerifyNow, and a TBX2 serum ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet- , reticulated platelet- , leucocyte count and haemoglobin level as a possible effect modifying parameter. | — |
Countries
Netherlands
Outcome results
None listed